



**NMS Labs**

**CONFIDENTIAL**

200 Welsh Road, Horsham, PA 19044-2208  
Phone: (215) 657-4900 Fax: (215) 657-2972  
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

**Demo Report**

**Report Issued** 03/30/2020 13:36  
**Last Report Issued** 05/31/2019 07:10

**88888**  
Clinical Example Report  
Attn: Example Reports  
200 Welsh Road  
Horsham, PA 19044

**Patient Name** 4535SP-POS  
**Patient ID** 4535SP-POS  
**Chain** 19000938  
**Age** Not Given **DOB** Not Given  
**Gender** Not Given  
**Workorder** 19000938  
**Received** 05/31/2019 07:07

**Sample ID** 19000938-001  
**Matrix** Serum or Plasma  
**Patient Name** 4535SP-POS  
**Patient ID** 4535SP-POS  
**Container Type** Clear vial

**Collect Dt/Tm** Not Given  
**Source** Not Given

**Approx Vol/Weight** Not Given

**Receipt Notes** None Entered

Analysis and Comments	Result	Units	Reporting Limit	Notes
-----------------------	--------	-------	-----------------	-------

**4535SP Trazodone and mCPP, Serum/Plasma**

Analysis by High Performance Liquid Chromatography/  
Tandem Mass Spectrometry (LC-MS/MS)

mCPP	50	mcg/mL	0.050	
Synonym(s): 1-(3-Chlorophenyl)Piperazine; Nefazodone metabolite; Trazodone metabolite				

Peak steady-state concentrations of mCPP in plasma averaged 0.03 mcg/mL at approximately 8 hours post dose following 300 mg normal release trazodone for 7 days and 0.03 +/- 0.01 mcg/mL following 200 mg nefazodone for 8 days.

Trazodone	50	mcg/mL	0.050	
Synonym(s): Trazamine®				

Steady-state plasma concentrations following daily oral doses of 300 mg immediate release trazodone ranged from 0.8 +/- 0.3 mcg/mL at trough to 3.1 +/- 0.8 mcg/mL at peak.

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.